| Not Yet Recruiting | Registry for Duchenne and Becker Muscular Dystrophy NCT07402122 | Dr. Andreas Ziegler | — |
| Recruiting | DMD Gene Variants and Cardiac Dysfunction in Young Males With Dystrophinopathies NCT07515235 | Aristotle University Of Thessaloniki | — |
| Not Yet Recruiting | Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies NCT07378553 | Nantes University Hospital | — |
| Not Yet Recruiting | Muscle MRI Outlining of Neuromuscular Diseases Using Artificial Intelligence NCT06917430 | Rigshospitalet, Denmark | — |
| Enrolling By Invitation | Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne and Becker Muscular Dystrophies NCT06363526 | University of Malaga | N/A |
| Not Yet Recruiting | Applying the Pathways and Resources for Engagement and Participation Protocol Among People With Muscles Dystro NCT06540365 | University of Haifa | N/A |
| Recruiting | Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI] NCT06378203 | IRCCS Eugenio Medea | N/A |
| Enrolling By Invitation | Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy NCT06066580 | Edgewise Therapeutics, Inc. | Phase 2 |
| Enrolling By Invitation | Follow-up Study on Female Carriers With DMD Gene Variants NCT05715957 | Rigshospitalet, Denmark | — |
| Active Not Recruiting | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) NCT05291091 | Edgewise Therapeutics, Inc. | Phase 2 |
| Completed | A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) NCT05166109 | ReveraGen BioPharma, Inc. | Phase 2 |
| Unknown | Schulze Muscular Dystrophy Ability Clinical Study NCT05409079 | AbiliTech Medical Inc. | N/A |
| Active Not Recruiting | Defining Endpoints in Becker Muscular Dystrophy NCT05257473 | Virginia Commonwealth University | — |
| Completed | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy NCT05160415 | Edgewise Therapeutics, Inc. | Phase 1 |
| Completed | Brain Involvement in Dystrophinopathies Part 2 NCT04668716 | Great Ormond Street Hospital for Children NHS Foundation Trust | — |
| Recruiting | CureDuchenne Link®: A Resource for Research NCT04972604 | CureDuchenne | — |
| Completed | Brain Involvement in Dystrophinopathies Part 1 NCT04583917 | Great Ormond Street Hospital for Children NHS Foundation Trust | — |
| Completed | A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy NCT04585464 | Edgewise Therapeutics, Inc. | Phase 1 |
| Recruiting | Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy NCT01484678 | University of Florida | — |
| Completed | Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy NCT04386304 | Epirium Bio Inc. | Phase 1 |
| Completed | Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases NCT04349566 | Mads Peter Godtfeldt Stemmerik | — |
| Completed | Weekly Steroids in Muscular Dystrophy NCT04054375 | Northwestern University | Phase 2 |
| Completed | UTSW HP [13-C] Pyruvate Injection in HCM NCT03057002 | University of Texas Southwestern Medical Center | — |
| Completed | Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dys NCT03238235 | Italfarmaco | Phase 2 |
| Completed | (-)- Epicatechin Becker Muscular Dystrophy NCT03236662 | Craig McDonald, MD | Phase 2 |
| Active Not Recruiting | Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD NCT02972580 | Nationwide Children's Hospital | — |
| Completed | Sodium Nitrate for Muscular Dystrophy NCT02434627 | Cedars-Sinai Medical Center | Phase 1 |
| Recruiting | Biomarker Development for Muscular Dystrophies NCT05019625 | Massachusetts General Hospital | — |
| Completed | Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I NCT02165358 | Rigshospitalet, Denmark | — |
| Unknown | Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies NCT02109692 | University Hospital, Montpellier | N/A |
| Completed | Sodium Nitrate to Improve Blood Flow NCT02847975 | Cedars-Sinai Medical Center | Phase 1 |
| Completed | Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy NCT02147639 | Cedars-Sinai Medical Center | Phase 2 / Phase 3 |
| Completed | Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study) NCT01856868 | Craig McDonald, MD | Phase 1 / Phase 2 |
| Completed | Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystroph NCT01557400 | PTC Therapeutics | Phase 3 |
| Unknown | Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping NCT01539772 | Cooperative International Neuromuscular Research Group | — |
| Completed | Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis NCT01519349 | Nationwide Children's Hospital | Phase 1 |
| Completed | Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy NCT01350154 | Rigshospitalet, Denmark | Phase 2 |
| Terminated | Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy NCT01168908 | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Phase 2 |
| Completed | Cardiac Magnetic Resonance in Children With Muscular Dystrophy NCT01081080 | Cooperative International Neuromuscular Research Group | — |
| Completed | Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies NCT01126697 | Cooperative International Neuromuscular Research Group | Phase 2 / Phase 3 |
| Terminated | Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscu NCT01009294 | PTC Therapeutics | Phase 2 |
| Completed | Cardiac Outcome Measures in Children With Muscular Dystrophy NCT01066455 | Cooperative International Neuromuscular Research Group | — |
| Completed | Tadalafil in Becker Muscular Dystrophy NCT01070511 | Cedars-Sinai Medical Center | Phase 4 |
| Completed | Evaluation of Limb-Girdle Muscular Dystrophy NCT00893334 | Cooperative International Neuromuscular Research Group | — |
| Completed | Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy NCT00873782 | University of North Carolina, Chapel Hill | Phase 1 |
| Terminated | Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) NCT00847379 | PTC Therapeutics | Phase 2 |
| Unknown | Ramipril Versus Carvedilol in Duchenne and Becker Patients NCT00819845 | Catholic University, Italy | Phase 4 |
| Completed | Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) NCT00592553 | PTC Therapeutics | Phase 2 |
| Recruiting | The Duchenne Registry NCT02069756 | The Duchenne Registry | — |
| Completed | Study Evaluating MYO-029 in Adult Muscular Dystrophy NCT00104078 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 / Phase 2 |
| Completed | Gentamicin Treatment of Muscular Dystrophy NCT00005574 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 |
| Completed | CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers NCT01540604 | RSPR Pharma AB | Phase 2 |